Silexion Therapeutics (NASDAQ:SLXN) Trading Down 0.4% – Here’s Why

Silexion Therapeutics Corp (NASDAQ:SLXN) shares were down 0.4% during mid-day trading on Wednesday . The stock traded as low as $2.53 and last traded at $2.70. 92,192 shares changed hands during trading, a decline of 57% from the average daily volume of 212,417 shares. The stock had previously closed at $2.71.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Monday, June 15th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold”.

Silexion Therapeutics Price Performance

The stock has a fifty day moving average price of $5.36 and a two-hundred day moving average price of $13.93. The company has a market cap of $1.16 million, a P/E ratio of -0.03 and a beta of -0.32.

Silexion Therapeutics (NASDAQ:SLXN) last posted its earnings results on Friday, May 15th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($12.90) by $12.05. As a group, analysts forecast that Silexion Therapeutics Corp will post -45.5 earnings per share for the current year.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.